While the Company’s in house programmes are primarily focused on oncology the power of its technology platform can be harnessed to discover and develop Humabody-based therapeutics for a wide range of other disease indications.
The pharmacological properties of Crescendo’s Humabodies also offer opportunities for a range of delivery routes such as local administration.
Crescendo has developed CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects.
CB001 has the potential to radically change the treatment of the poorly-served 80% of psoriasis sufferers, addressing a major unmet need with a highly efficacious, safe, self-administered topical drug for long-term therapy. It could also reduce the requirement for long-term systemic immunosuppressive mAb therapy in the most severely affected 20% of psoriasis sufferers.
To discuss and explore partnering opportunities for CB001, contact email@example.com